Fusion Antibodies, an antibody humanization and cell line development CRO, have today announced the further preclinical development of Fsn1006h bispecific antibody and the granting of a European patent for the same.
Fusion’s Fsn1006h antibody…
Check out our company’s profile in the summer edition of European Biopharmaceutical Review. You can read a digital copy via http://flk.bz/W38U
European Biopharmaceutical Review (EBR) is a quarterly magazine dedicated to the…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Carolyn Lowry/wp-content/uploads/2022/01/fusion-antibodies-logo.svgCarolyn Lowry2015-07-15 11:07:342022-04-05 10:50:58Fusion Antibodies featured in EBR magazine
Leading UK contract research organisation and antibody humanization specialist, Fusion Antibodies, has been shortlisted for a prestigious Irish Times InterTradeIreland Innovation Award.
Leading UK contract research organisation and antibody…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Carolyn Lowry/wp-content/uploads/2022/01/fusion-antibodies-logo.svgCarolyn Lowry2015-02-15 11:12:122022-04-05 10:51:04Fusion Antibodies nominated for Irish Times Intertradeireland Innovation Award
Fusion Antibodies and ISCA diagnostics are announcing successful development of a humanized version of ISCA Diagnostic’s Aspergillus-specific monoclonal antibody JF5. The project has taken place over the past 10 months and today marks its…
FUSION ANTIBODIES DEVELOP HIGH EXPRESSION LEVEL STABLE CELL LINE FOR ISCA DIAGNOSTICS
Fusion Antibodies Develop High Expression Level Stable Cell Line for ISCA Diagnostics
Fusion Antibodies and ISCA diagnostics are happy to announce…
In 2001, Fusion Antibodies emerged from Queen’s University in Belfast. We are happy to still be working together in the field of novel medicine.
Queen’s University Belfast is a member of the Russell Group of 24 leading UK research-intensive…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Carolyn Lowry/wp-content/uploads/2022/01/fusion-antibodies-logo.svgCarolyn Lowry2014-09-15 11:26:342022-04-05 10:51:15Antibodies Alma Mater – Queen’s University
Fusion Antibodies have entered into collaboration with Japanese Biotechnology company Chiome Bioscience to humanize chicken antibodies. The project will use the capabilities of the Fusion Antibodies next generation Antibody Humanization CDRx…
Eighteen students took part in a work experience event sponsored by Fusion Antibodies and hosted by the University of Ulster on 1 and 2 July 2014.
Fusion Antibodies understand that the best way to learn is by experience. That is…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Carolyn Lowry/wp-content/uploads/2022/01/fusion-antibodies-logo.svgCarolyn Lowry2014-08-15 11:32:162022-04-05 10:51:25Fusion Antibodies helps students examine a career in Stratified Medicine
One of the most important goals of modern medical research is to find an effective and non invasive method of a cancer treatment. Immunotherapy and Stratified Medicine have a great potential to become a leading approach to cancer therapy.
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Carolyn Lowry/wp-content/uploads/2022/01/fusion-antibodies-logo.svgCarolyn Lowry2014-08-15 11:29:102022-04-05 10:51:29Antibodies inhibit cathepsin S to stop metastasis – news from Memorial Sloan Kettering research team
A novel pre-clinical antibody drug being developed by Fusion Antibodies (Belfast, NI) is being targeted at Pancreatic Cancer. Early in-vitro data has shown significant efficacy in Pancreatic Cancer cell lines and the Company is now seeking…
/wp-content/uploads/2022/01/fusion-antibodies-logo.svg00Carolyn Lowry/wp-content/uploads/2022/01/fusion-antibodies-logo.svgCarolyn Lowry2014-05-15 11:37:462022-04-05 10:51:35Fusion Antibodies lead drug targeted at pancreatic cancer
Fusion Antibodies Ltd has today announced a collaboration with the regenerative medicine company Avipero Ltd for humanization of their integrin antibody platform.
The antibody engineering and humanization program partnered with Fusion…
Fusion Antibodies will be attending the following events in 2014, we look forward to seeing you there!
BioTrinity 2014European Biopartnering and Investment ConferenceLondon, May 12-14 2014
Biotech Outsourcing StrategiesCopenhagen, June…
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: